Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2020

Summary

The publisher's Medical Devices sector report, “Drug Eluting Stents (DES)-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

DES release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Drug Eluting Stents (DES) under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment/industry

Reasons to Buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date

1 Table of Contents

2 Introduction

2.1 Drug Eluting Stents (DES) Overview

3 Products under Development

3.1 Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
3.2 Drug Eluting Stents (DES)-Pipeline Products by Territory
3.3 Drug Eluting Stents (DES)-Pipeline Products by Regulatory Path
3.4 Drug Eluting Stents (DES)-Pipeline Products by Estimated Approval Date
3.5 Drug Eluting Stents (DES)-Ongoing Clinical Trials

4 Drug Eluting Stents (DES)-Pipeline Products under Development by Companies

4.1 Drug Eluting Stents (DES) Companies-Pipeline Products by Stage of Development
4.2 Drug Eluting Stents (DES)-Pipeline Products by Stage of Development

5 Drug Eluting Stents (DES) Companies and Product Overview6 Drug Eluting Stents (DES)-Recent Developments7 Appendix

List of Tables

Table 1: Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
Table 2: Drug Eluting Stents (DES)-Pipeline Products by Territory
Table 3: Drug Eluting Stents (DES)-Pipeline Products by Regulatory Path
Table 4: Drug Eluting Stents (DES)-Pipeline Products by Estimated Approval Date
Table 5: Drug Eluting Stents (DES)-Ongoing Clinical Trials
Table 6: Drug Eluting Stents (DES) Companies-Pipeline Products by Stage of Development
Table 7: Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
Table 8: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Xience SBA Everolimus Eluting Coronary Stent System-Product Status
Table 10: Xience SBA Everolimus Eluting Coronary Stent System-Product Description
Table 11: XIENCE Thin man DES-Product Status
Table 12: XIENCE Thin man DES-Product Description
Table 13: ZoMaxx Drug Eluting Coronary Stent System-Product Status
Table 14: ZoMaxx Drug Eluting Coronary Stent System-Product Description
Table 15: Abbott Vascular Inc-Ongoing Clinical Trials Overview
Table 16: Xience SBA Everolimus Eluting Coronary Stent System-A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
Table 17: Xience SBA Everolimus Eluting Coronary Stent System-A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
Table 18: Xience SBA Everolimus Eluting Coronary Stent System-A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
Table 19: Xience SBA Everolimus Eluting Coronary Stent System-Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
Table 20: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Dual Drug Eluting Stent-Product Status
Table 22: Dual Drug Eluting Stent-Product Description
Table 23: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Stenting System-Drug Eluting Stent-Product Status
Table 25: Stenting System-Drug Eluting Stent-Product Description
Table 26: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 27: Drug Eluting Stent-Product Status
Table 28: Drug Eluting Stent-Product Description
Table 29: AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Cre8 DES-Product Status
Table 31: Cre8 DES-Product Description
Table 32: Cre8 EVO DES-Product Status
Table 33: Cre8 EVO DES-Product Description
Table 34: DES-Coracto-Product Status
Table 35: DES-Coracto-Product Description
Table 36: AlviMedica Medical Technologies Inc-Ongoing Clinical Trials Overview
Table 37: Cre8 DES-A Prospective, Multi-center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
Table 38: Cre8 DES-A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
Table 39: Cre8 DES-A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
Table 40: Cre8 DES-Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients

List of Figures

Figure 1: Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
Figure 2: Drug Eluting Stents (DES)-Pipeline Products by Territory
Figure 3: Drug Eluting Stents (DES)-Pipeline Products by Regulatory Path
Figure 4: Drug Eluting Stents (DES)-Pipeline Products by Estimated Approval Date
Figure 5: Drug Eluting Stents (DES)-Ongoing Clinical Trials